Technology Bundle ID
TAB-3295

New Anti-Influenza Virus Neuraminidase 9 (N9) Monoclonal Antibody – for Prevention or Treatment of H7N9 Influenza (Flu) A with Less Likelihood of Drug Resistance

Linked ID
E-200-2016-0
Lead Inventors
Jason Wilson (CDC)
Co-Inventors
Ian York (CDC)
James Stevens (CDC)
Zhu Guo (CDC)
ICs
CDC
H7N9 influenza viruses are predominately avian (bird) pathogens, however, since 2013, they have infected more than 1500 humans with a mortality rate of nearly 40% in confirmed cases. H7N9 viruses continue to be a threat to public health. Treatment for people infected with H7N9-subtype influenza A (H7N9) commonly includes the use of drugs that inhibit neuraminidase, a protein found on the virus’ surface. However, like other influenza viruses, H7N9 can become resistant to these drugs.

CDC researchers have developed a monoclonal antibody (mAb) that binds to the neuraminidase protein of H7N9 influenza viruses, and has been shown in animal studies to provide protection from H7N9 infection. Because this antibody targets a different region of the neuraminidase protein than other antibodies, it is unlikely that H7N9 strains have developed resistance to it, making it an ideal starting point for antibody-based therapy or prevention of H7N9 infection. This technology could be used alone, or in combination with other neuraminidase inhibitor drugs. The antibody can also be useful as a research material. It will need to be humanized in further research.
Commercial Applications
  • Prevention of H7N9 influenza (flu) infection
  • Treatment of H7N9 influenza (flu) infection
  • Research tool and diagnostic reagent
Competitive Advantages
  • Unlikely for virus to develop resistance due to unique binding site of antibody
  • Can be used for prevention or treatment
  • Currently available mAbs are not reactive with the N9 influenza subtype
  • Can be used alone or in combination with other drugs

Request More Info

Licensing Contact: